MedTrace Logo

Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia

NCT05081349 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2021-10-22

No results posted yet for this study

Summary

The role of the combination therapy of hydroxyurea and L-Carnitine was studied in thalassemic patients. nevertheless its role in sickle cell anemia patients was not investigated

Conditions

Interventions

DRUG

Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine

Combination therapy

DRUG

Hydroxycarbamide 500 Mg Oral Capsule

Single agent

DRUG

L-Carnitine, 250 Mg Oral Capsule

single agent

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Israa EM Ashry, Prof · Assiut University- Faculty of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2020-06-10
Completion
2021-07-10
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05081349 on ClinicalTrials.gov